Last Updated on October 17, 2024 by The Health Master
Noida: Jubilant Draximage Inc., a wholly owned subsidiary of Jubilant Pharmova Limited, has announced that the US Food and Drug Administration (USFDA) has approved the company’s new drug application (NDA) for the Kit for the Preparation of Technetium (Tc 99m) Mertiatide Injection that was submitted in accordance with section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA).
The Tc 99m Mertiatide Injection is used to diagnose calculi in adults and pediatric patients 30 days and older as well as congenital and acquired renal abnormalities, renal failure, and urinary tract obstruction.
With this product, it is possible to provide renal function, split function, renal angiograms, and renogram curves for the entire kidney and renal cortex. This approval is effective from Jan 30, 2023.
Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, operates in the fields of radiopharma, allergy immunotherapy, contract research development and manufacturing (CRDMO), generics, and proprietary novel drugs.
With a network of 46 radio pharmacies in the US, Jubilant’s Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services.
Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU, and other geographies) through five manufacturing facilities.
The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world-class research centers in India.
The company is also involved in the manufacturing of Active pharmaceutical Products (API) through a USFDA approved facility in Nanjangud, Karnataka.
USFDA tentative nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets
USFDA approves this drug for rare blood cancer
USFDA gives approval for Amphetamine capsules
USFDA gives tentative approval Acalabrutinib capsules, 100 mg
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
USFDA gives tentative approval for Levomilnacipran extended-release capsules
New programme to promote research in Pharma Industry
DCGI allows relabeling & re-stickering of drugs: Rule 104A
USFDA tentative nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets
NPPA proposes revised ceiling price of Gentamicin injection
Light sensitive drugs / medicines: List
USFDA issues Form 483 with zero observation to Solara Active Pharma Sciences Vizag Facility
PowerPoint Slide Shows for Regulators and Industry
Area required for manufacturing of Drugs, Cosmetics, Homoeopathic & Blood Centre
BA / BE Studies: Bioavailability & Bioequivalence
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
